Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Pharmaessentia Corp (6446 TT): Strong 2Q25; Geography Expansion of Besremi to Drive Near-Term Growth

Pharmaessentia Corp (6446 TT): Ends 2025 on Strong Note; Key Drug Awaiting Label Expansion in 2026

Pharmaessentia Corp (6446 TT): Strong 1Q Result; Commercialization Activity Ahead of Label Expansion

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pharmaessentia-corp" target="_blank" data-smartkarma-citation="entities:16461:1" rel="noopener">Pharmaessentia Corp (6446 TT)</a> reported 2Q26 results, with accelerated double-digit revenue growth and significant improvement in profitability. Revenue marks the 15th consecutive quarter of record-high figure with 90% YoY growth.</li>
<li>Pharmaessentia has launched Besremi Pen in the U.S. The company expects Besremi Pen to become a key driver of its continued growth, going ahead.  </li>
<li>Last October, Pharmaessentia filed for the indication expansion of Besremi for the treatment of essential thrombocythemia to the FDA. The agency has set an action date of August 30, 2026.</li>
</ul>



Pharmaessentia Corp (6446 TT) reported 2Q26 results, with accelerated double-digit revenue growth and significant improvement in profitability. Revenue marks the 15th consecutive quarter of record-high figure with 90% YoY growth.
Pharmaessentia has launched Besremi Pen in the U.S. The company expects Besremi Pen to become a key driver of its continued growth, going ahead.  
Last October, Pharmaessentia filed for the indication expansion of Besremi for the treatment of essential thrombocythemia to the FDA. The agency has set an action date of August 30, 2026.


Pharmaessentia Corp (6446 TT): Stellar 2Q Performance; Eye on Imminent Label Expansion of Besremi